Hair & nails

Hair growth achieved with novel formulation of JAK inhibitor

Sublingual tofacitinib may have a role in the management of alopecia areata with fewer side effects than the oral form of the JAK1/3 inhibitor. An Australian pilot study of sublingual tofacitinib was conducted  in 18 patients with moderate to severe, treatment-resistant alopecia. The 18 patients rolled over to sublingual tofacitinib had been non-responders to either ...

Already a member?

Login to keep reading.

© 2021 the limbic